Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
Platelet-rich plasma (PRP) ovarian therapy is an emerging fertility treatment that injects concentrated growth factors from your own blood directly into the ovaries to potentially improve ovarian reserve markers such as AMH (anti-Müllerian hormone) and antral follicle count.
Key findings from early research:
Before pursuing PRP ovarian therapy, patients should carefully weigh potential risks, costs, candidate eligibility, and supportive lifestyle changes.
If you're considering PRP ovarian therapy, it's likely because you're experiencing symptoms of diminished ovarian reserve, irregular cycles, or difficulty conceiving. Understanding the underlying cause is critical before pursuing any advanced intervention. Take a free, instant, online symptom check to identify possible conditions affecting your fertility and get clear guidance on the right next steps — including which specialists to consult and what questions to ask.
Reviewed for medical accuracy: 07/09/2026
Egg quality naturally declines with age and can be affected by factors like genetics, lifestyle, and medical conditions. Platelet-rich plasma (PRP) therapy has emerged as a potential way to improve ovarian reserve and egg health. Below, we'll explore what PRP for ovarian reserve is, how it might work, the existing scientific evidence, potential risks, and other steps you can take to support your fertility.
PRP stands for platelet-rich plasma. It's an autologous treatment, meaning it uses your own blood. Here's a quick overview:
PRP is already used in orthopedics and dermatology to promote healing. In reproductive medicine, the idea is that growth factors in PRP may help "awaken" dormant follicles and improve the ovarian environment.
While the exact mechanisms aren't fully understood, several theories exist:
The science on PRP for ovarian reserve is still emerging. Most studies to date are small, often without control groups, but they offer early insights:
Overall, preliminary data suggest that PRP may enhance markers of ovarian reserve (AMH, antral follicle count), but larger randomized controlled trials are needed to confirm efficacy and safety.
Based on the current evidence, you might see:
No medical procedure is risk-free. PRP for ovarian reserve may carry:
Before considering PRP, weigh these factors and discuss them thoroughly with your fertility specialist.
Ovarian PRP is generally considered for women who:
While research on PRP continues, these lifestyle and supplement strategies have more established data:
Lifestyle Changes
Nutrition and Supplements
Medical Therapies
If you're curious about your reproductive health or experiencing symptoms like irregular periods, pelvic pain, or difficulty conceiving, you can quickly check your symptoms with Ubie's free AI-powered tool to understand potential causes and receive personalized guidance on when to seek professional care.
Ovarian PRP is promising but still experimental. Before pursuing any new fertility treatment:
For any life-threatening or serious concerns—severe abdominal pain, heavy vaginal bleeding, or sudden health changes—contact your doctor or emergency services immediately.
While PRP for ovarian reserve offers an exciting glimpse into future fertility treatments, it's not a guaranteed solution. Combining medical innovation with established lifestyle measures and professional guidance gives you the best chance to support your egg quality and overall reproductive health.
(References)
* Aksu T, Güler A, Bayar U, Kahyaoğlu S, Yildiz S. Ovarian Platelet-Rich Plasma in Poor Ovarian Responders: A Systematic Review. J Minim Invasive Gynecol. 2023 Dec;30(12):1070-1081.e1. doi: 10.1016/j.jmig.2023.08.007. Epub 2023 Aug 11. PMID: 37579766.
* Sfakianoudis K, Pantos K, Sfakianoudis A, Rapani A, Sfakianoudis V, Sfakianoudis E, Vlahos N, Nitsos K. Ovarian rejuvenation through autologous platelet-rich plasma intraovarian injection. Expert Rev Mol Diagn. 2023 Jun;23(6):449-456. doi: 10.1080/14737159.2023.2223842. Epub 2023 Jun 20. PMID: 37338025.
* Sfakianoudis K, Pantos K, Rapani A, Sfakianoudis V, Vlahos N, Nitsos K. Autologous Platelet-Rich Plasma Treatment in Patients with Diminished Ovarian Reserve. Biomedicines. 2020 Jul 15;8(7):220. doi: 10.3390/biomedicines8070220. PMID: 32679774. PMCID: PMC7400030.
* Aksu T, Bayar U, Demirayak G, Özdinç S. Intraovarian Platelet-Rich Plasma Application in ART Cycles of Poor Ovarian Responders: A Retrospective Cohort Study. J Minim Invasive Gynecol. 2024 Jan;31(1):54-62. doi: 10.1016/j.jmig.2023.09.006. Epub 2023 Sep 11. PMID: 37699703.
* Cakiroglu Y, Yildiz Y, Aksu T. Impact of ovarian autologous platelet-rich plasma on assisted reproductive outcomes in patients with diminished ovarian reserve: A prospective cohort study. J Obstet Gynaecol Res. 2023 Aug;49(8):2150-2157. doi: 10.1111/jog.15747. Epub 2023 Jun 13. PMID: 37311149.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.